comparemela.com

Latest Breaking News On - James dentzer - Page 5 : comparemela.com

Curis to Host Webcast to Discuss Updated Emavusertib Clinical Data in Leukemia

/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today.

United statesRobert martellJames dentzerEric winerPrnewswire curis incAmerican society of hematology annual meetingDana farber cancer instituteTakeaim leukemiaAmerican societyHematology annualClinical investigatorDana farber cancer

Curis Provides Third Quarter 2022 Business Update

Curis, Inc. , a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its business update and financial results for the third quarter. | November 10, 2022

United statesRoche erivedgeJames dentzerDrug administrationCuris incDevelopment expensesAmerican society of hematologyExchange commissionRoche groupTakeaim leukemia phaseChief executive officerRecent operationalTakeaim lymphomaTakeaim leukemiaAim lymphomaAim leukemia

Curis Announces Three Presentations at SITC 2022

/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today.

United statesJames dentzerPrnewswire curis incDrug administrationJanssen biotech incRoche groupCuris incAnnual meetingChief executive officerAdvanced solidClinical trialsImmune monitoringJanssen biotechAim lymphomaAim leukemiaOrphan drug designation

Curis Announces Date for the 1st Symposium on IRAK4 in Cancer

/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today.

United statesRobert martellAmit vermaGrzegorz nowakowskiEdwardp evansJames dentzerMarc raaijmakersGuillermo garcia maneroOmar abdel wahabUlrich steidlDaniel starczynowskiHagop kantarjianDivision of cancer medicineHead of researchMontefiore department of oncologyMd anderson cancer center

Curis Announces Date for the 2nd Annual VISTA Symposium

/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today.

James dentzerRandolph noelleGeisel school of medicinePrnewswire curis incNorris cotton cancer centerActive emeritus professorGeisel schoolChief executive officerTumor immune

vimarsana © 2020. All Rights Reserved.